MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

CD36 receptor

Search medical newsFind research, conditions and clinical updates
  • Home
  • CD36 receptor
Metrnl: A Novel Inhibitor of Platelet Activation Targeting CD36 to Mitigate Thrombosis and Acute Myocardial Injury
Posted inCardiology Hematology-Oncology news

Metrnl: A Novel Inhibitor of Platelet Activation Targeting CD36 to Mitigate Thrombosis and Acute Myocardial Injury

Posted by By MedXY 08/21/2026
Metrnl reduces platelet activation and thrombus formation by promoting CD36 degradation, offering a promising therapeutic strategy for thrombotic diseases including acute myocardial infarction without increasing bleeding risk.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Navigating the Ethical Crossroads of Prenatal Testing for Adult-Onset Genetic Conditions: The Case of Huntington Disease
  • Genetic Biomarkers Define Distinct Clinical Subgroups in Giant Cell Arteritis: Implications for Diagnosis and Personalized Management
  • Refining CLAD Surveillance: Integrating Alveolar Nitric Oxide for Enhanced Lung Transplant Monitoring
  • Distinct Cancer Risks in Morphea and Systemic Sclerosis: Insights from a Large Population-Based Cohort Study
  • Refining Lymphovenous Anastomosis: Intraoperative Factors Driving Improved Outcomes in Lymphedema Surgery
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top